Severely suppressed bone turnover: A potential complication of alendronate therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1294-1301

  Odvina, Clarita V ^a   Zerwekh, Joseph E ^a   Rao, D Sudhaker ^c   Maalouf, Naim ^a   Gottschalk, Frank A ^b   Pak, Charles Y C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; GLUCOCORTICOID; TETRACYCLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; BONE DISEASE; BONE TURNOVER; CANCELLOUS BONE; CHEMICAL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FIBROMYALGIA; FRACTURE NONUNION; HUMAN; LONG TERM CARE; MALE; MENOPAUSAL SYNDROME; MORPHOMETRICS; OSSIFICATION; OSTEOPENIA; PRIORITY JOURNAL; STRESS FRACTURE; BIOPSY; BONE DENSITY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; FRACTURE; FRACTURE HEALING; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY;

AGED; ALENDRONATE; BIOPSY; BONE DENSITY; BONE RESORPTION; FEMALE; FRACTURE HEALING; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; SEVERITY OF ILLNESS INDEX;

EID: 15944413442     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0952     Document Type: Article

References (35)

1. Liberman UA, Weiss SR, Broll J, Minne H, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
2. Tonino RP, Meunier PJ, Emkey R, Rodrigues-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109-3115
3. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85:4118-4124
4. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
5. Li J, Mashiba T, Burr DB 2001 Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281-286
6. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531
7. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res 15:613-620
8. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 21:13-20
9. Boivin G, Meunier PJ 2002 Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 43:535-537
10. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB 2003 Aging and microstructural compartments in human compact bone. J Bone Miner Res 18:1012-1019
11. Ciarella TE, Fyhrie DP, Parfitt AM 2003 Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311-315
12. Ott SM 2001 Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 86:1835
13. Tonino RP, Santora A, Ross PD 2001 Safety of long-term alendronate. J Clin Endocrinol Metab 86:1835-1836
14. Whyte MP, Wenkert D, Clemens KL, McAllister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463
15. Zerwekh JE, Antich PP, Sakhaee K, Prior J, Gonzales J, Gottschalk F, Pak CYC 1992 Lack of deleterious effect of slow-release sodium fluoride treatment on cortical bone histology and quality in osteoporotic patients. Bone Miner 18:65-76
16. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S 1988 Static and tetracydine-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3:133-144
17. Han Z-H, Palnitkar S, Rao DS, Nelson D, Parfitt AM 1997 Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12:498-508
18. Parfitt AM, Han Z-H, Palnitkar S, Rao DS, Shih M-S, Nelson D 1997 Effects of ethnicity and age or menopause on osteoblast function, bone mineralization and osteoid accumulation in iliac bone. J Bone Miner Res 12:1864-1873
19. Foldes J, Shih M-S, Parfitt M 1990 Frequency distribution of tetracydine-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5:1063-1067
20. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595-610
21. Parfitt AM 2003 Renal bone disease: a new conceptual framework for interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 12:387-408
22. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85:720-726
23. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA 1999 Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076-3081
24. Ruggiero SL, Mebrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
25. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales J, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
26. Weinstein RS 2000 True strength. J Bone Miner Res 15:621-625
27. Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Charhon S 1984 Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's disease. In: Avioli LV, Gennari C, Imbimbo B, eds. Glucocorticoid effects and their biological consequences. New York: Plenum Publishing; 191-200
28. Ubara Y, Fushimi T, Tagami T, Sawa N, Hoshino J, Yokota M, Katori H, Takemoto F, Hara S 2003 Histomorphometric features of bone in patients with secondary and primary hypoparathyroidism. Kidney Int 63:1809-1816
29. Fleisch H 1998 Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
30. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301-307
31. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates J, Meunier PJ 1997 Histomorphomettic assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
32. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chestnut III CH 1993 The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406
33. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
34. Ingle BM, Hay SM, Bottjer HM, Eastell R 1999 changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int 10:399-407
35. Richer E, Lewis M, Odvina C, Vasquez MA, Pak CYC, Antich PP 2003 Impaired bone quality in bisphosphonate (BISPHOS) treatment and renal transplantation by ultrasound critical angle reflectometry (UCR). J Bone Miner Res 18:SU111